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Abstract 
A total of 145 leishmaniasis Iraqi patients were collected from suspected cases and 30 healthy control. Based on skin smear 
examination and serum samples analysis, the patients were distributed into two clinical groups: 30 cutaneous leishmaniasis 
and 30 visceral leishmaniasis patients. The study was conducted for the detection of 17 types of antinuclear autoantibodies 
(ANA) in studied groups, 10 types including (anti-ds-DNA, anti-Nucleosome, anti-SmD1, anti-PCNA, anti-SS-A/Ro60kD, 
anti-SS-A/Ro52kD, anti-SS-B/La, anti-CENP-B, anti-Mi-2 and anti-Ku antibodies), showed significant differences (P≤0.05), 
(P≤0.01) in the two groups, while 7 types which were non-significant included (anti-histones, anti-ribosomal P0, anti-Scl70, 
anti-U1-snRNP, anti-AMA M2, anti-Jo1 and anti-PM-Scl antibodies). With respect to the Anti-cardiolipin IgG antibodies 
(aCL), it showed a significant increased level in the serum of VL patients (P≤0.01) as compared with control group (8.123 vs. 
1.959), also as compared with CL patients (8.123 vs. 2.402). As for CL patients, also there was a significant difference 
(P≤0.01) (2.402 vs. 8.123) when compared with VL patients, but no significant variations (2.402 vs. 1.959) were observed in 
compare with control group. We conclude that Leishmaniasis in iraqi patients may be considered as a cause autoimmune 
diseases as in case of inflammatory myopathies (IM), and the pathgenesis of human myositis, especially in VL which 
contributes in the immunological alterations associated with muscle damage.    
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Introduction 
Leishmaniasis is a group of vector-borne disease caused by obligate, intracellular protozoa belonging to the genus 
Leishmania, it is characterized by diversity and complexity, Leishmania infection is transmitted to susceptible mammalian 
hosts by about 30 species of female phlebotomine sand flies (1,2). 
Leishmania spp. cause awide variety of diseases that range in severity from self-healing cutaneous leishmaniasis to 
fatal disseminated visceral leishmaniasis (3,4). The parasites have a digenetic life cycle and exist in two distinct 
morphologies, the promastigote in sand fly vector, and the amastigote in mammalian host (5). In order to develop a 
successful parasitic relationship with its host, the Leishmania must evade both the innate and adaptive immune 
responses.When Leishmania first enter the human body, it is in a promastigote from, which was engulf by macrophages of 
the reticuloendothelial system, but it is resistant to proteolysis degradation in the phagosome. So, within the mammalian host, 
Leishmania resides as amastigotes in phagocytic cell (6). In visceral leishmaniasis (VL), the intracellular parasite causes 
intense parasitism in the reticuloendothelial system, affecting the liver, spleen, bone marrow, and lymph nodes. It causes 
expressive changes in cellular and humoral response, with deficiency of Interferongamma (IFN-γ), increased production of  
Tumour necrosis factor-α (TNF-α) and other interleukins, besides polyclonal hypergammaglobulinemia (7).  
The clinical presentation of VL is characterized by hepatosplenomegaly, fever, paleness, asthenia, weight loss, 
tachycardia, coughing, epistasis, bleeding of the gums, myalgia, arthralgia, and adenopathy, among others; those 
symptoms can also be seen in Systemic lupus erythematosus (SLE) (8). And the main signs and symptoms observed in 
cutaneous leishmaniasis (CL) include: ulcerated, painless lesion with elevated borders, central granulation tissue, with or 
without exudates, the lesion can be single, multiple, disseminated, or diffuse (6).  
Leishmanial infection in human is characterized by the appearance of anti-leishmanial antibodies in the sera of the 
patient. In CL, usually they are present at low levels during the active phase of disease (9). In contrast strong anti-leishmanial 
antibodies titer well documented in VL. The elevated antibody titers against promastigote or amastigote antigens, have been 
extensively exploited for specific serodiagnosis in last two decades (10). and the analysis of sera of with Leishmania 
infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune 
complexes and anti-IgG antibodies  (11). According to American College of Rheumatology (12). The antibodies make a 
mistake, identifying normal, naturally-occurring proteins in our bodies as being “foreign” and dangerous. The antibodies that 
target “normal” proteins within the nucleus of a cell are called Anti-nuclear Antibodies (ANA). ANAs could signal the body 
to begin attacking itself which can lead to autoimmune diseases, including: SLE, scleroderma, Sjögren’s syndrome, 
polymyositis, dermatomyositis, mixed connective tissue disease (MCTD), drug-induced lupus, and Primary biliary 
cirrhosis (PBC). 
SLE is a multifactorial autoimmune, chronic inflammatory disease with a polymorphic clinical presentation. It is 
associated with immunologic dysfunction with polyclonal activation of B lymphocytes and autoantibodies against nuclear 
antigens, some of which participate in immune-mediated tissue lesions. Due to its polymorphic presentation, it can be 
mistaken with several infectious diseases, including VL (13).  
The production of autoantibodies, such as anti-Sm, anti-RNP, anti-SSA, anti-SSB, and antiphospholipid, is found in 
patients with Leishmania infection. The induction of autoantibodies in leishmaniasis can be attributed to the release and 
exposure of antigens, previously hidden, during tissue damage and breakage of host cells (14).  
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Accordingly, the present study was designed to inspect the association between the autoantibodies and the two 
types of Leishmania; CL and VL, and to define the antinuclear antibodies recognized by sera from Iraqi patients with 
leishmaniasis and determine whether these leishmanial infections may correlate with autoimmune manifestations, through the 
following parameters,through investigating the association of IgG autoantibodies against some antigens, especially; nuclear 
antigens, like: dsDNA, Nucleosome, histones, SmD1, PCNA, ribosomal P0, SS-A/Ro60kD, SS-A/Ro52kD, SS-B/La, CENP-
B, Scl70, U1-snRNP, AMA M2, Jo1, PM-Scl, Mi-2, Ku and against cardiolipin. 
 
Subjects, Materials and Methods: 
Subjects: 
A total of 145 leishmaniasis Iraqi patients were collected from suspected cases including, 75 uncertainly diagnosed with CL. 
Their age range was (3 to 66 years), 70 uncertainly diagnosed with VL. Their age range was (3 month to 10 years) attending 
AL-Karama Teaching Hospital and Central Public Health Laboratory, during the period October 2013 to February 2014 were 
enrolled in this study. The clinically cases examined and evaluated at these medical centers under the supervision of staff. In 
addition, 30 healthy (controls), their age range was (3 month to 59 years), were also included in this study. Based on skin 
smear examination and serum samples analysis, the patients were distributed into two clinical groups: 30 patients of 
cutaneous leishmaniasis (CL), were diagnosed depending on the clinical picture and laboratory diagnosis of cutaneous 
ulcer.and their age range was (3 to 59 years), 30 patients of visceral leishmaniasis (VL, were diagnosed by Indirect Immune 
Fluorescent Antibody Assay Test (IFAT) and their age range was (4 month to 9 years) . 
 
Blood samples collection: 
Five milliliter (ml) of venous blood was collected in sterile container from each patient; sera were separated after leaving 
samples at room temperature for about 15 to 30 minutes, and then centrifuged at 1500 rpm for 5 minutes and the sera 
dispensed into 4 to 5 Eppendorf tubes, stored at -20ᵒC until used for laboratory diagnosis and serological tests. 
 
Detection of total antinuclear antibodies profile among studied groups: 
IMTEC-ANA-LIA MAXX is an indirect membrane based enzyme immunoassay for the qualitative measurement of IgG 
class antibodies against 17 variables autoantibodies includes:dsDNA, nucleosomes, histones, SmD1, PCNA, ribosomal P0, 
SS-A/Ro60kD, SS-A/Ro52kD, SS-B/La, CENP-B, Scl70, U1-snRNP, AMA M2, Jo1, PM-Scl, Mi-2 and Ku in human serum 
or plasma.This test based on the principle the line immune assay (LIA). Nuclear and associated cytosolic antigens are applied 
as lines on a nitrocellulose membrane. The nitrocellulose membrane is blocked to prevent unspecific reaction. During strip 
incubation with diluted patient samples autoantibodies bound antibodies a secondary horseradish peroxidase (HRP)- labeled 
anti-human IgG antibody is used. After addition of the substrate and stop solution the appearance of brown lines indicate the 
existence of (auto) antibodies against the respective antigen (15).  
 
Test validation 
For each strip: function control is visible, cut-off control is visible, intensity function control  >  intensity cut-off control. The 
strip were fixed onto scoring sheet and the reference line of the strip was aligned with the reference line on the scoring sheet. 
The dotted reference line of the evaluation template was aligned with the reference line. The interpretation of the test result 
take place exclusively on basis of the respected cut-off control regarded for each strip; the test result was negative, if no band 
was too recognized or if the band exhibits a smaller intensity in comparison to the cut-off. The test was equivocal, if the 
intensity of cut-off control did not significantly differ, the test result was positive if a band exhibits a stronger staining in 
comparison to the cut-off control (15).  
Detection of total Anticardiolipin (aCL)-IgG Antibody among studied groups: 
This method was carried out according to (AESKULISA Company). Cardiolipin-IgG-IgM is a solid phase enzyme 
immunoassay employing highly Serum purified cardiolipin plus native human β2-glycoprotein1 for the quantitative and 
qualitative detection of IgG and / or IgM antibodies against cardiolipin in human serum. Serum samples diluted 1:101 are 
incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the 
antigen. The unbound fraction is washed off in the following step. After wards anti-human immunoglobins conjugate to 
horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the 
microplates. Unbound conjugate is washed off in the following step. Addition of Tetramethylbenzidine (TMB) substrate 
generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color change to yellow). The rate of 
color formation for the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is 
proportional to the initial concentration of the respective antibodies in the patient sample. A standard curve is prepared from 
standard dilutions and human anti Cardiolipin-IgG antibody concentration is determined from a curve fitting equation (kit 
leaflet). 
 
Calculation of Sample Results: 
For quantitative interpretation establish the standard curve by plotting the optical density (OD) of each calibrator (y-axis) 
with respect to the correspond concentration values in GPL\ml or MPL\ ml (x-axis).  
 
Statistical Analysis: 
The Statistical Analysis System- SAS (2010) was used to effect of different factors in study parameters. Chi-square test was 
used to significant compare between percentage and Duncan multiple range test was used to significant compare between 
means in this study. 
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Results 
The study was conducted for the detection of 17 types of antinuclear autoantibodies in studied groups, 10 types including 
(anti-ds-DNA, anti-Nucleosome, anti-SmD1, anti-PCNA, anti-SS-A/Ro60kD, anti-SS-A/Ro52kD, anti-SS-B/La, anti-CENP-
B, anti-Mi-2 and anti-Ku antibodies), showed significant differences (P≤0.05), (P≤0.01) as in table 1, while 7 types which 
were non-significant included (anti-histones, anti-ribosomal P0, anti-Scl70, anti-U1-snRNP, anti-AMA M2, anti-Jo1 and 
anti-PM-Scl antibodies)  as in table 2. 
 
Anti-cardiolipin IgG antibodies (aCL) in patients with Leishmaniasis : 
Anti-cardiolipin IgG antibodies showed a significant increased level in the serum of VL patients (P≤0.01) as compared with 
control group (8.123 vs. 1.959), also as compared with CL patients (8.123 vs. 2.402) table 3. As for CL patients, also there 
was a significant difference (P≤0.01) (2.402 vs. 8.123) when compared with VL patients, but no significant variations (2.402 
vs. 1.959) were observed in compare with control group.   
 
Discussion 
All 60 consecutive patients with CL and VL who were tested, were found to have a variety of autoantibodies present without 
any clinical autoimmune manifestation. 
For anti-ds-DNA, among patients with CL (n=30), 1 (3.3%) was positive and 29 (96.7%) were negative, while in 
patients with VL (n=30), 9 (30.0%) were positive and the results were negative in 21 (70.0%). The anti-ds-DAN 
autoantibodies in leishmaniasis patients was significantly different at the level of (P≤ 0.01), when compared between the 
groups.  
In a study with 45 visceral leishmaniasis patients and 45 with cutaneous leishmaniasis (11) did not note the 
presence of anti-ds-DNA in CL patients, while they pointed to its presence in (4.4%) of VL patients, so the present results 
shared these findings, and the anti-ds-DNA antibodies are  more present in VL than in CL patients. 
(14) mentioned the case of a patient with visceral leishmaniasis who was positive for anti-DNA antibodies, which 
disappeared after treatment with corticosteroids, antimonials, and posterior use of liposomal amphotericin B. In a study of 23 
patients with visceral leishmaniasis and 14 with cutaneous leishmaniasis, (16)  did not observe the presence of anti-ds-DNA 
despite the production of other autoantibodies in those patients. Also (17) did not detect anti-ds DNA autoantibodies in any 
VL patients.    
For anti-Nucleosomes antibodies in CL (n=30), these antibodies were positive in 5 patients (16.7%) and were 
negative in 25 (83.3%), whereas in VL (n=30), 16 patients (53.3%) were registered positive and 14 (46.7%) were negative. 
The anti-Nucleosomes autoantibodies in leishmaniasis patients was significantly different at the level of (P≤0.01), when 
compared with studied groups.  
For anti-SmD1in our CL patients (n=30), no one scored positive 0 (0.0%) and 30 patients (100.0%) gave a negative 
result, while in patients with VL (n=30), the results of 4 patients (13.3%) tested positive and 26 patients (86.7%) were 
negative. The anti-SmD1 antibodies in leishmaniasis patients was significantly different at the level of (P≤0.05), when 
compared between studied groups. (11) did not observe the presence of anti-SmD1, regardless the type of leishmaniasis 
(visceral or cutaneous), while (16) observed the presence of anti-SmD1 antibodies in 7% of patients with cutaneous 
leishmaniasis and in 83% of the patients with visceral leishmaniasis. Also (17) revealed about anti-Sm antibodies in 6% of 
patients with visceral leishmaniasis in their study on 16 patients.  
anti-PCNA, among patients with CL (n=30), 1 (3.3%) was positive and 29 (96.7%) were negative, while in patients 
with VL (n=30), 9 (30.0%) were positive and the results were negative in 21 (70.0%). The anti-PCNA autoantibodies in 
leishmaniasis patients was significantly different at the level of (P≤ 0.01), when compared between the groups. 
Autoantibodies targeting the proliferating cell nuclear antigen have been considered as a specific biomarker for 
systemic lupus erythematosus. The proliferating cell nuclear antigen-like staining pattern was rarely found (0.07%) in 
sequential, unselected sera. Further, indirect immunofluorescence is not an accurate screening method to identify anti-PCNA 
antibodies as their presence may be masked by other autoantibodies (18).   
For both anti-SSA/ Ro60 and Ro52, in patients with CL (n=30), no one scored positive (0.00%) and 30 of the 
patients (100.0%) were negative for anti-SS-A/Ro60kD, whereas one patient (3.3%) gave a positive result and 29 of the 
patients (96.7%) were negative for anti-SS-A/Ro52kD. While in VL patients (n=30), 9 patients (63.3%) scored positive 
results  and 21 of the patients (36.7%) had tested negative for anti-SS-A/Ro60kD, but 7 patients (23.3%) were positive and 
23 of the patients (76.7%) had tested negative for anti-SS-A/Ro52kD.  
With respect to the anti-SS-B/La, we found that 4 patients (13.3%) have those antibodies and 26 patients (86.7%) 
haven’t these antibodies in CL patients and 19 of the patients (63.3%) were scored positive result for this antibody in addition 
to 11 patients (36.7%) who were negative in VL patients respectively. The anti-SS-A/Ro60kD, anti-SS-A/Ro52kD and anti-
SS-B/La in leishmaniasis patients were significantly different at the level of (P≤0.05), when compared between studied 
groups.  (11) did not shown the presence of anti- SSA/Ro antibodies regardless the type of leishmaniasis (visceral or 
cutaneous), the results were negative. As for anti-SSB/La antibodies, only one patient (1.1%) with visceral leishmaniasis had 
a positive result and all others were negative, while (16) revealed that in sera of patients with VL, the antibodies against Sm, 
RNP,and SS-B antigens were detected in 83, 86 and 73% of the patients respectively, and only 36% of the VL patients were 
considered positive to SS-A, while ˂25% of CL patients exhibit such antibodies. And on the other study, (17) observed the 
presence of anti-Ro antibodies in sera of 13% of patients with visceral leishmaniasis. 
Molecular mimicry between Leishmania sp. Antigens and ribonucleoproteins is one of the hypotheses raised by 
(14) to explain the presence of those autoantibodies (anti-Sm, anti-RNP, anti-SSA, and anti-SSB) in infected patients. The 
possibility that Sm, RNP, SSB, and Leishmania share similar antigenic determinants is raised, due to the inhibition of 
autoantibodies against those nuclear antigens by intact Leishmania promastigotes (16). 
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In the current study, patients with Visceral Leishmaniasis (VL) demonstrated a significantly different distribution 
of (ANA) as compared to Cutaneous Leishmaniasis patients (CL), and showed the highest level of autoantibodies especially; 
Anti-Ku antibodies  24 (80%), anti-Mi-2 antibodies 21 (70%) and anti-SS-B/La antibodies 19 (63.3%) in descending order ( 
Table 4-9). But there was some increase in the level of anti-Ku antibodies  12(40.0) in CL patients. 
It is not found that any one gave a positive examination for those antibodies in the group of healthy control.  
In a study  conducted to analyze the prevalence of myositis-specific and myositis-associated autoantibodies and 
their clinical correlations in a large series of patients with dermatomyositis/polymyositis, the most frequently found 
autoantibody was anti-Ro-52 (36.9%), followed by anti-Jo-1 (18.9%), anti-Mi-2 (8.1%), anti-Ku (4.1%), anti-SRP (3.2%), 
anti-PL-7 (3.2%), anti-PL-12 (2.7%), anti-PM/Scl75 (2.7%), and anti-PM/Scl100 (2.7%). The distributions of these 
autoantibodies were comparable between polymyositis and dermatomyositis, except for a higher prevalence of anti-Jo-1 in 
polymyositis. Anti-Mi-2 was more prevalent in dermatomyositis (19). These observations may lead to correlate between 
leishmaniasis infection and autoimmune diseases in terms of the contribution of leishmaniasis in the formation of 
autoantibodies and may support the perception that leishmanial infection may lead to autoimmune diseases through the 
formation of these autoantibodies in patients with leishmaniasis ,especially in (VL) patients.    
Leishmaniasis is a spectrum of diseases and the humoral response of patients varies markedly depending on the 
type of disease present. Patients with VL have markedly elevated immunoglobulins levels and anti-leishmanial specific 
antibodies, though much of these immunoglobulins is not leishmania specific (20, 21).  On the other hand, in the cutaneous 
forms of leishmaniasis, antibodies specific to the parasite are demonstrable, where the serum immunoglobulin levels are 
normal (21). Analysis of infected patients by several group of investigators, revealed the existence of autoantibodies against 
cellular and humoral components (22, 23).  
In the present study, we examined the response to nuclear antigens of patients with leishmaniasis. Several 
possibilities can be taken into account to explain the manifestation of autoantibodies in leishmaniasis. The first is might be 
due to release of high amounts of self antigens as a result of tissue destruction caused by the parasite. Release of tissue 
antigens may stimulate the autoreactivity and autoantibody production. Another possible mechanism is altered host immune 
responses caused by Leishmania parasites. Both T and B cells are affected by VL (24). VL causes polyclonal B cell 
activation independent of T cells through mitogen activation or stimulation of cytokines by other immune cells (25, 16). B 
cell hyper activation results in severe hypergammaglobulinaemia observed in VL. Finally, there are some molecular mimicry 
between leishmanial antigens and host antigens such as ribosomal phosphoproteins expressed on parasites, causing cross-
reactivity (26, 24). 
Moreover, even in cutaneous leishmaniasis, which is not characterized by hypergammaglobulinaemia, leishmanial 
antigens can induce blastogenesis and proliferation responses (22, 27). Specific antibodies against the parasite can be induced 
by antigens released by promastigotes and amastigotes (28).      
Another study on Leishmania donovani revealed the induction of a non-specific as well as a specific antibody 
production, much of which is probably due to the parasite-released substances, which act as B cell mitogens (29, 30). As a 
consequences of The B cell hyperactivity, leishmania donovani may cause hypergammaglobulinaemia and it is common in 
all patients with Kala-azar due to the large production of IgG, IgM and IgA antibodies, after polyclonal activation of B 
lymphocytes, generating specific and non-specific antibodies, besides the production of  autoantibodies such as ANA and 
others.  On the other hand, the prolonged saturation of the reticuloendothelial system infected by parasites contributes to 
organomegaly and mainly to splenomegaly, causing cytopenias. And the study conclude that: all patients with positive ANA 
do not have SLE, splenomegaly is not a common sign in patients with SLE and the VL may present with cytopenias and the 
production of autoantibodies mimicking SLE (31, 11). 
The immune response to the infection caused by Leishmania spp. includes both T-cell and B-cell activation. 
However the pathogenesis of the disease appears to be related T-cell cytotoxicity, and control of VL depends on the 
magnitude of T helper 1 (Th1) and multicytokine responses early in the course of infection (32). Indeed, it has been showen 
during progressive infection in mice that Th2 CD4+ yT cells expand and secrete interleukin-4, resulting in polyclonal B cell 
activation. Later on, in fully established VL, a cellular anergy is established. Inappropraite antigen presentation and 
communication between the antigen-presenting cells and Tcells, as well as the induction of interleukin-10 and interleukin-4, 
might be the reason for this anergy (32, 33).  
With respect to the aCL antibodies, our findings together with the results obtained by (Harimoto and da Costa, 
2009) that out of 45 patients with VL, the anticardiolipin IgG antibody was positive in 17.8 % (n=8) and undetermined in 
8.9%(n=4), while among patients with CL, only one (2.2%) tested positive for aCL IgG. 
In another study conducted by (34), an Iraqi comparative study on autoantibodies in VL, they showed that 18 
(29%) of 62 cases of VL revealed a positive aCL. 
 We did not found in the literature any studies on anticardiolipin antibodies for comparison. The literature reports 
the presence of anticardiolipin antibodies in other infectious diseases (35, 36), Repka et al.38 observed those antibodies in 
8.34% of patients with paucibacillary leprosy and 80.77% of non-treated patients with multibacillary leprosy. The origin of 
anticardiolipin antibodies in patients with infections has been widely debated and several hypotheses have been suggested. 
Among them we should mention: non-specific polyclonal activation of B cells; ability of the infectious agent to bind to 
endogenous phospholipids making them immunogenic; damage of the endothelium by the infectious agent, exposing 
phospholipid epitopes that trigger the immunologic response; and cross reaction of anti-DNA antibodies giving rise to 
anticardiolipin antibodies. 
The presence of anticardiolipin antibodies in patients with leishmaniasis is important since those antibodies are 
related with the etiopathogenic mechanisms of venous and arterial thrombosis (35).  In 2006, (37) studied 33 dogs naturally 
infected by Leishmania infantum and observed that 63.3% of them had antiplatelet antibodies and half of those animals had 
thrombocytopenia and clinical signs of moderate to severe disease.  
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Table 1: Distribution of significantly different ANA autoantibody among studied groups. 
      ANA autoantibody 
  Cutaneuos  
      n = 30 
  Visceral 
     n=30 
  Controls 
     n=30 
 
Chi-
squaree 
 P. value 
No. % No. % No. % 
Anti-dsDNA Positive 1 3.3 9 30.0 0 0.0  9.43 ** 0.015  Negative 29 96.7 21 70.0 30 100 
Anti-
Nucleosome 
Positive 5 16.7 16 53.3 0 0.0  
11.8 ** 0.006  Negative 25 83.3 14 46.7 30 100 
Anti-SmD1 Positive 0 0.0 4 13.3 0 0.0  4.26 * 0.04  Negative 30 100.0 26 86.7 30 100 
Anti-PCNA Positive 1 3.3 9 30.0 0 0.0  9.43 ** 0.015  Negative 29 96.7 21 70.0 30 100 
Anti-SS-A/Ro 
60 
Positive 0 0.0 9 63.3 0 0.0  
12.6 ** 0.001  Negative 30 100.0 21 36.7 30 100 
Anti-SS-A/Ro 
52 
Positive 1 3.3 7 23.3 0 0.0  
3.29 ** 0.022  Negative 29 96.7 23 76.7 30 100 
Anti-SS-B/La Positive 4 13.3 19 63.3 0 0.0  10.9 ** 0.002  Negative 26 86.7 11 36.7 30 100 
Anti-CENP-B Positive 0 0.0 5 16.7 0 0.0  5.96 * 0.019  Negative 30 100.0 25 83.3 30 100 
Anti-Mi-2 Positive 4 13.3 21 70.0 0 0.0  12.4 ** 0.001 Negative 26 86.7 9 30.0 30 100 
Anti-Ku Positive 12 40.0 24 80.0 0 0.0  10.2 ** 0.003  Negative 18 60.0 6 20.0 30 100 
* (P≤0.05), ** (P≤0.01). 
 
Table 2 : Distribution of non-significantly different ANA autoantibody   among studied groups. 
ANA autoantibody 
 Cutaneous  
      n=30 
  Visceral  
     n=30 
  Controls 
     n=30 
 
Chi-
square  
P.value 
No. % No. % No. % 
Anti-Histone Positive 7 23.3 10 33.3 0 0.0  2.08 NS  0.56 Negative 23 76.7 20 66.7 30 100 
Anti-P0 Positive 0 0.0 0 0.0 0 0.0  0.00 NS - Negative 30 100.0 30 100.0 30 100 
Anti-Scl70 Positive 0 0.0 0 0.0 0 0.0  0.00 NS - Negative 30 100.0 30 100.0 30 100 
Anti-U1-
snRNP 
Positive 3 10.0 7 23.3 0 0.0  
2.71 NS 0.29 Negative 27 90.0 23 76.7 30 100 
Anti-AMA M2 Positive 1 3.3 1 3.3 0 0.0  1.42 NS 0.47 Negative 29 96.7 29 96.7 30 100 
Anti-Jo-1 Positive 0 0.0 0 0.0 0 0.0  0.00 NS - Negative 30 100.0 30 100.0 30 100 
Anti-PM-Scl Positive 4 13.3 7 23.3 0 0.0  2.65 NS 0.31 Negative 26 86.7 23 76.7 30 100 
NS:
 
 Non- significant. 
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Table 3: Mean value of Anti-Cardiolipin IgG antibodies in studied groups. 
            Groups No.     Mean ± S.E*. Minimum Maximum 
Cutaneous Leishmaniasis 30 2.402 ± 1.455 B 1.081 12.900 
Visceral Leishmaniasis 30 8.123 ± 3.828 A 1.093 85.108 
Control 30 1.959± 0.156 B 1.131 4.095 
Total 90 4.161 ± 1.306 1.081 85.108 
Different letter: Significant difference between means (Duncan test).  ** (P≤0.01). 
 
 
Figure1: Location of the ANA line with reference line function control and cut-off control line. 
 
Figure 2 : ELISA standard curve of anticardiolipin IgG. 
 
 
 
  
